Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioring gets FDA filip for annuloplasty ring trial

This article was originally published in Clinica

Executive Summary

The FDA has given a boost to Bioring's efforts to gain US marketing approval for its biodegradable annuloplasty ring by awarding the Swiss company a grant of an undisclosed sum for a clinical trial of the device. The trial will assess the efficacy and safety of the Kalangos ring in the treatment of atrioventricular valve regurgitation in paediatric patients. The ring, used for mitral and tricuspid valve repair, is a three-dimensional flexible device designed for quick and easy implantation via a minimally-invasive surgical procedure, according to Lonay-based Bioring. It restores normal organ function, while gradually degrading over a six-month period as the natural organ regrows. The Kalangos annuloplasty ring was CE marked in 2005, and is currently used in the US under a compassionate use exemption.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel